Population pharmacokinetics of gentamicin in South African newborns

被引:25
作者
Botha, JH
du Preez, MJ
Adhikari, M
机构
[1] Nelson R Mandela Sch Med, Dept Expt & Clin Pharmacol, ZA-4013 Congella, South Africa
[2] Nelson R Mandela Sch Med, Dept Paediat & Child Hlth, ZA-4013 Congella, South Africa
关键词
gentamicin; newborn; pharmacokinetics;
D O I
10.1007/s00228-003-0663-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. Gentamicin population pharmacokinetics in newborns were studied with special reference to possible gender effects. Methods. Steady-state serum levels (n=139) were obtained from 79 neonates with a mean birth weight of 2.1 kg, mean gestational age of 35.1 weeks and mean age at the time of sampling of 4.2 days. The data were analysed using the non-linear mixed effects model (NONMEM). A one-compartment model was used to fit the data. Results. The final models for clearance (CL) and volume of distribution (V) were: CL(l/h)=0.001xWGTxGAxP and V(l)=0.472xWGT, where WGT=birth weight (kg), GA=gestational age (weeks) and P=1.2 for girls and 1.0 for boys. The values of inter-individual variability in CL and V were 34% and 35%, respectively. Intra-individual variability was 5% (proportional) and 7.2% (additive). Mean (95% confidence interval) values of CL and half-life were 0.042 l h(-1) kg(-1) (0.041, 0.043 l h(-1) kg(-1)) and 8.0 h (7.7, 8.3 h), while V was 0.472 (0.428, 0.516) l/kg for all patients. Conclusion. Mean population pharmacokinetic values were similar to those obtained with NONMEM for gentamicin in other neonates of similar age. Gender was found to be a determinant of CL, with girls clearing faster than boys.
引用
收藏
页码:755 / 759
页数:5
相关论文
共 17 条
[1]  
ASSAEL BM, 1992, PEDIAT PHARM THERAPE, P244
[2]   THE NONMEM SYSTEM [J].
BEAL, S ;
SHEINER, L .
AMERICAN STATISTICIAN, 1980, 34 (02) :118-119
[3]  
BEAL SL, 1992, NONMEM USERS GUIDES
[4]   Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models [J].
Botha, JH ;
du Preez, M ;
Miller, R ;
Adhikari, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 53 (05) :337-341
[5]   Tobramycin population pharmacokinetics in neonates [J].
deHoog, M ;
Schoemaker, RC ;
Mouton, JW ;
vandenAnker, JN .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) :392-399
[6]   Population kinetics of tobramycin in neonates [J].
Falcao, AC ;
Buelga, DS ;
Méndez, ME ;
García, MJ ;
Pardo, M .
THERAPEUTIC DRUG MONITORING, 2001, 23 (03) :202-208
[7]   NETILMICIN IN THE NEONATE - POPULATION PHARMACOKINETIC ANALYSIS AND DOSING RECOMMENDATIONS [J].
FATTINGER, K ;
VOZEH, S ;
OLAFSSON, A ;
VLCEK, J ;
WENK, M ;
FOLLATH, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (01) :55-65
[8]  
GRASELA TH, 1985, CLIN PHARMACOL THER, V37, P199
[9]  
Hentschel R, 1996, CLIN NEPHROL, V46, P54
[10]  
JENSEN PD, 1992, PHARMACOTHERAPY, V12, P178